KOC
GTBP icon

Koss-Olinger Consulting’s GT Biopharma GTBP Stock Holding History

Koss-Olinger Consulting’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.9K Buy
+10,000
New +$4.06K ﹤0.01% 172

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

Koss-Olinger Consulting's GTBP Position: Q2 2026 in Review

Koss-Olinger Consulting opened a new position in GT Biopharma (GTBP) in Q2 2026: 10,000 shares worth $4.9K. The stake represents ﹤0.01% of the portfolio and ranks #172 among its holdings.

59 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Koss-Olinger Consulting held 10,000 shares of GT Biopharma worth $4.9K as of Q2 2026.
  • GT Biopharma was a new Koss-Olinger Consulting position in Q2 2026.
  • GT Biopharma made up ﹤0.01% of Koss-Olinger Consulting's portfolio in Q2 2026, its #172 holding.
  • 59 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Koss-Olinger Consulting's 13F filing for Q2 2026, filed 10 Aug 2026.